Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingGlobeNewsWire • Thursday
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyGlobeNewsWire • 03/14/24
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom FisherZacks Investment Research • 03/13/24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024GlobeNewsWire • 02/27/24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialGlobeNewsWire • 02/13/24
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialGlobeNewsWire • 12/14/23
Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of ActionGlobeNewsWire • 10/06/23
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck CancerGlobeNewsWire • 10/03/23
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer PatientsGlobeNewsWire • 07/11/23
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/16/23
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint InhibitorsGlobeNewsWire • 04/19/23
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual ConferenceGlobeNewsWire • 04/18/23
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical TrialGlobeNewsWire • 02/14/23
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer MetastasisGlobeNewsWire • 11/15/22